Real world survey to describe the characteristics, experience and treatment satisfaction for patients treated with belimumab within the Adelphi (LPP) for Systemic Lupus Erythematosus (SLE)

Trial Profile

Real world survey to describe the characteristics, experience and treatment satisfaction for patients treated with belimumab within the Adelphi (LPP) for Systemic Lupus Erythematosus (SLE)

Completed
Phase of Trial: Phase IV

Latest Information Update: 17 Aug 2017

At a glance

  • Drugs Belimumab (Primary) ; Belimumab (Primary)
  • Indications Systemic lupus erythematosus
  • Focus Therapeutic Use
  • Acronyms LPP
  • Sponsors GlaxoSmithKline
  • Most Recent Events

    • 17 Aug 2017 New trial record
    • 10 Aug 2017 Results (n=878) assessing patient and physician reported satisfaction using patient data from LLP (GSK- HO-15-15509) and DSP (GSK-HO 15-16709) surveys published in the Clinical Therapeutics
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top